Rybrevant

Chemical Nameamivantamab-vmjw
Dosage FormInjection (intravenous; 350 mg/7 mL)
Drug ClassMonoclonal antibodies
SystemRespiratory
CompanyJanssen Biotech
Approval Year2021

Indication

  • For the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
Last updated on 5/31/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Rybrevant (amivantamab-vmjw) Prescribing Information2021Janssen Biotech, Inc., Horsham, PA